Physician Education: Bridging Clinical Research and Patient Care

An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

Washington, DC

Wednesday, May 4, 2011

8:15 AM - 4:00 PM

Location

Capital Hilton
1001 16th St NW
Washington, DC 20036
United States

Overview

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.

Conflicts of Interest

Information regarding financial relationships with commercial companies that have interests in the content discussed, is obtained from all parties with control over the activity content (ie, co-chairs, faculty, and IAS–USA staff), and any real or apparent conflicts of interest of those parties are resolved prior to the activity being delivered. Financial affiliations of all those parties are published in the course syllabus. Individuals who refuse to disclose financial interests may not participate in the CME activity.

Who Should Attend

This course is designed for physicians and other clinical decision makers who are actively involved in the medical care of people with HIV/AIDS, specifically those who:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV/AIDS
  • Are currently active in HIV/AIDS research

This course is relevant for practitioners who are involved in HIV/AIDS patient care, including nurse practitioners and other nursing professionals, physician assistants, pharmacists, and others.

Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.

Learning Objectives

Upon completion of the course, participants will be able to:

  • Design antiretroviral strategies that consider current data on:
    • Initial therapy
    • The role of new and investigational drugs
    • Antiretroviral regimen failure
    • Drug-drug interactions
  • Describe the incidence and management of narcotic addiction in HIV-infected patients
  • Classify neurocognitive impairment in HIV-infected individuals
  • Identify and discuss changes to treatment guidelines for sexually transmitted diseases and opportunistic infections
  • Describe current data on investigational hepatitis C virus drugs as they impact the potential for treatment

Continuing Education Credits

Accreditation

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The IAS–USA designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note that nursing continuing education credits are not provided for this course. Nurse practitioners and other nursing professionals will receive a certificate of attendance.

American Academy of Family Physicians Credit

This activity, 19th Annual Improving the Management of HIV Disease Advanced CME Course, with a beginning date of May 4, 2011, has been reviewed and is acceptable for up to 6.25 Prescribed credits by the American Academy of Family Phyisicans.

Grant Support

In the interest of an objective, balanced, and scientifically rigorous CME program, educational grants are pooled to support this activity. We gratefully acknowledge the below commercial companies for their contributions.

MAJOR SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc

SUBSTANTIAL SUPPORTERS
Bristol-Myers Squibb
Tibotec Therapeutics

GENEROUS SUPPORTERS
Abbott Laboratories
ViiV Healthcare

Requests for additional educational grants have been made to commercial companies with competing products. Information on additional grant supporters will be posted on the IAS–USA website as it becomes available.

Co-Chair(s)

Henry Masur, MD, Course Chair
Michael S. Saag, MD, Vice Chair

Presentations